Blood culture

MicroPhage's MRSA/MSSA blood culture test enables clinicians to direct the most appropriate therapy by identifying and determining antibiotic susceptibility or resistance of S. aureus from blood cultures in four hours.

A growing crisis
In the U.S. alone, more than 5.2 million cases of bacteremia (bacteria in the blood) are detected annually. In those cases where S. aureus is identified, the fatality risk ranges from 30- to 40-percent. Rapid antibiotic therapy is required to prevent sepsis. However, current methods for bacterial identification and antibiotic susceptibility require more time that is clinically permissible, so treatment designed to cover as many suspected causative organisms as possible is most often applied.

Unfortunately, this blanket treatment approach comes at a price. Fatality rates are increasing, due in large part to antibiotic resistance. The only long-term solution is rapid diagnostic information to guide appropriate therapy.

A life-saving solution
While current bacterial blood borne infection diagnostic methods require 24 to 48 hours, MicroPhage's tests offer results in a mere four hours. By receiving critical susceptibility and resistance information early in the blood culture process, physicians can prescribe the most effective treatment, thereby improving patient care, reducing costs, and decreasing mortality rates.